Neuroleptic malignant syndrome with gangliosidosis type II

Biological Psychiatry

Volumn 41, Issue 12, 1997, Pages 1222-1224

  Manor, Iris ^b   Hermesh, Haggai ^a   Munitz, Hanan ^b   Weizman, Abraham ^b  

^a GEHA MENTAL HEALTH CENTER   (Israel)

^b NONE

Author keywords

Creatine kinase; Familial; GM2 gangliosidosis; Hereditary; Neuroleptic malignant syndrome; Psychosis

Indexed keywords

HALOPERIDOL; LEVOMEPROMAZINE;

ADULT; ARTICLE; CASE REPORT; CATATONIA; FEMALE; GANGLIOSIDOSIS; HUMAN; MALE; NEUROLEPTIC MALIGNANT SYNDROME; PRIORITY JOURNAL; PSYCHOSIS;

ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; HALOPERIDOL; HUMANS; MALE; NEUROLEPTIC MALIGNANT SYNDROME; PSYCHOTIC DISORDERS; SANDHOFF DISEASE;

EID: 0031001157     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(97)00187-X     Document Type: Article

References (9)

1. American Psychiatric Association (1994): Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Press.
2. 2 gangliosidosis resulting from hexosaminidase A deficiency. Ann Neurol 16:14-20.
3. Goodman A (1994): Medical conditions in Ashkenazi schizophrenic pedigrees. Schizophr Bull 20:507-517.
4. Navon R, Argov Z, Frisch A (1986): Hexosaminidase A deficiency in adults. Am J Med Genet 24:179-196.
5. Otani K, Horiuchi M, Kondo T, et al (1991): Is the predisposition to neuroleptic malignant syndrome genetically transmitted? Br J Psychiatry 158:850-853.
6. 2 gangliosidosis. Ann Neurol 31:342-344.
7. Rosebush PI, MacQueen GM, Clarke JTR, et al (1995): Late-onset Tay-Sachs disease presenting as catatonic schizophrenia: Diagnostic and treatment issues. J Clin Psychiatry 56:347-353.
8. Shalev A, Munitz H (1986): The neuroleptic malignant syndrome: Agent and host interaction. Acta Psychiatr Scand 33:337-347.
9. 2 gangliosidosis. Neurology 43:2055-2058.